Lack of placebo effect on ambulatory blood pressure - PubMed (original) (raw)

Clinical Trial

Lack of placebo effect on ambulatory blood pressure

G Mancia et al. Am J Hypertens. 1995 Mar.

Abstract

Several studies have reported that, at variance with clinic blood pressure, ambulatory blood pressure is not reduced by treatment with placebo. However, this evidence has usually been obtained in small groups of subjects and no data are available from a larger sample of patients. To address this issue we have analyzed data from 116 outpatients involved in placebo-controlled studies on antihypertensive treatment. The patients were studied before and at the end of a 6- to 8-week period of placebo. In all patients, blood pressure was measured by sphygmomanometry and over the 24 h by automatic ambulatory monitoring. Administration of placebo was accompanied by a significant reduction in systolic and diastolic clinic blood pressure (-5.3 +/- 1.1 and -4.4 +/- 0.6 mm Hg, respectively; P < .01), but not in 24-h, daytime and nighttime blood pressure. Hourly systolic and diastolic blood pressure profiles were virtually superimposable in the two different periods, except for the first 4 h, in which systolic blood pressure was slightly but significantly lower during than before placebo (149.5 +/- 1.2 v 146.4 +/- 1.2 mm Hg; P < .05). These results provide a large database indicating that 24-h average blood pressure is not reduced by placebo, thus it is not necessary to include a placebo control group in antihypertensive drug studies in which ambulatory blood pressure monitoring is employed. A small placebo effect occurs, however, in the first hours of ambulatory monitoring. This may lead to a slight overestimation of the peak blood pressure effect of a drug and an underestimation of its trough-to-peak ratio if placebo correction of the data is not made or if the first part of ambulatory blood pressure monitoring is not excluded from data analysis.

PubMed Disclaimer

Cited by

Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST. Johnson JA, et al. Am Heart J. 2009 Mar;157(3):442-9. doi: 10.1016/j.ahj.2008.11.018. Am Heart J. 2009. PMID: 19249413 Free PMC article. Clinical Trial.
Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke.
Georgianou E, Georgianos PI, Petidis K, Markakis K, Zografou I, Karagiannis A. Georgianou E, et al. Int J Hypertens. 2019 Oct 7;2019:9830295. doi: 10.1155/2019/9830295. eCollection 2019. Int J Hypertens. 2019. PMID: 31687205 Free PMC article.
Failure of psychological interventions to lower blood pressure: a randomized controlled trial.
Perez MI, Linden W, Perry T Jr, Puil LJ, Wright JM. Perez MI, et al. Open Med. 2009 Jun 9;3(2):e92-e100. Open Med. 2009. PMID: 19946397 Free PMC article.
The pharmacogenetics research network: from SNP discovery to clinical drug response.
Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network. Giacomini KM, et al. Clin Pharmacol Ther. 2007 Mar;81(3):328-45. doi: 10.1038/sj.clpt.6100087. Clin Pharmacol Ther. 2007. PMID: 17339863 Free PMC article. Review.

Lack of placebo effect on ambulatory blood pressure - PubMed (original) (raw)